

Special Issue

Vaccines and Immunization: Measles, Mumps, and Rubella

Message from the Guest Editor

Measles, mumps, and rubella are viral diseases with many complications. Measles can become severe and often lead to death, mumps are associated with hearing loss, and rubella infection in pregnant women can cause fetal infection and CRS at high rates. Fortunately, the number of cases has dropped dramatically in countries and regions where vaccines are widely used. However, the COVID-19 pandemic, poverty, and conflicts have significantly impacted vaccination efforts. In areas where immunization rates have declined, a resurgence of these diseases is also affecting neighboring countries. Moreover, while measles, mumps, and rubella have typically been viewed as childhood diseases, recent epidemiological trends show that their impact extends to adults and the elderly. This Special Issue aims to explore the future of these diseases, focusing on advancements in understanding their pathology and virology, changes in the epidemiological landscape, and progress in developing future vaccines. We look forward to your contributions and insights on this important topic.

Guest Editor

Dr. Nobuhiko Okabe

Kawasaki City Institute for Public Health, Kawasaki City 210-0821,
Kanagawa, Japan

Deadline for manuscript submissions

30 April 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/237100

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).